Concomitant drug treatment (a KDM1A inhibitor together with an HDAC inhibitor) is another alternative option, as the inhibition of KDM1A aggravates the cell cycle arrest and apoptosis of breast cancer and glioblastoma cells induced by HDAC inhibitors [153, 167, 168]. This evidence concerns the gene KDM1A and breast carcinoma.